Addex Therapeutics Q1 Loss Narrows Amid Sharply Lower Income

Addex Therapeutics (ADXN) reported a reduced net loss of CHF 1.47 million for Q1 2025, compared to a loss of CHF 3.09 million in the prior year, primarily due to the absence of losses from discontinued operations and lower operating expenses. While R&D and G&A expenses decreased, income also declined to CHF 0.07 million due to the completion of a service agreement with Indivior. The company's cash position stands at CHF 2.8 million, and management highlighted progress with their GABAB PAM drug candidate for chronic cough and the regained rights to their Phase 2 mGlu2 PAM asset, ADX71149.

Analysis

Addex Therapeutics reported a Q1 net loss of CHF 1.47 million, a significant reduction from the CHF 3.09 million loss in the prior year, primarily due to the absence of a CHF 2.35 million loss from discontinued operations divested in April of the previous year. Consequently, the loss from continuing operations increased to CHF 1.47 million in Q1 2025 from CHF 0.74 million in Q1 2024. Despite this, the company achieved a narrower total operating loss of CHF 0.61 million, down from CHF 0.79 million year-over-year, reflecting successful cost management with R&D expenses decreasing by CHF 0.1 million to CHF 0.16 million and G&A expenses falling by CHF 0.3 million to CHF 0.78 million. However, income critically declined to CHF 0.07 million from CHF 0.24 million, a direct result of the completion of a service agreement with Indivior on June 30, 2024. The company's cash position stood at a modest CHF 2.8 million at the end of the first quarter. Management highlighted positive developments in its clinical pipeline, including continued progress with the GABAB PAM drug candidate for chronic cough, supported by recently presented positive preclinical data, and the strategic regaining of rights to its Phase 2 mGlu2 PAM asset, ADX71149. The overall financial picture is mixed, with improved headline loss and operational cost controls offset by a deteriorating income profile and an increased loss from its core ongoing business.

Key Decisions for Investors

• Investors should critically assess the impact of the increased loss from continuing operations, which rose to CHF 1.47 million, and the sharply reduced income of CHF 0.07 million, despite the narrower reported net loss driven by discontinued items.
• The current cash position of CHF 2.8 million necessitates careful monitoring of the company's burn rate and the high probability of future financing requirements, which could result in shareholder dilution.
• Potential investors should weigh the promising pipeline developments, such as the GABAB PAM and mGlu2 PAM programs, as long-term catalysts against the inherent risks of clinical-stage biotechnology ventures and the immediate financial pressures from reduced income and limited cash reserves.